Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers

European Journal of Cancer Prevention

Volumn 17, Issue 5, 2008, Pages 438-445

  Herszenyi, László ^a   István, Gábor ^a   Cardin, Romilda ^b   De Paoli, Massimo ^b   Plebani, Mario ^b   Tulassay, Zsolt ^a   Farinati, Fabio ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Adenoma; Cathepsin B; Dysplasia; Gastrointestinal cancer; Precancerous lesion; Protease; Urokinase type plasminogen activator

Indexed keywords

CATHEPSIN B; UROKINASE;

ADULT; AGED; ARTICLE; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIGESTIVE SYSTEM CANCER; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM DYSPLASIA; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; STOMACH EPITHELIUM; ADENOMA; BLOOD; CARCINOMA; CASE CONTROL STUDY; DISEASE COURSE; EVALUATION; GASTROINTESTINAL TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CASE-CONTROL STUDIES; CATHEPSIN B; DISEASE PROGRESSION; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; URINARY PLASMINOGEN ACTIVATOR;

EID: 56149098136     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e328305a130     Document Type: Article

References (70)

1. Abe J, Urano T, Konno H, Erhan Y, Tanaka T, Nishino N, et al. (1999). Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size. Cancer 86:2602-2611.
2. Adenis A, Huet G, Zerimech F, Hecquet B, Balduyck M, Peyrat JP (1995). Cathepsin B, L, and D activities in colorectal carcinomas: relationship with clinical-pathological parameters. Cancer Lett 96:267-275.
3. Berger DH (2002). Plasmin/plasminogen system in colorectal cancer. World J Surg 26:767-771.
4. Beyer BC, Heiss MM, Simon EH, Gruetzner KU, Babic R, Jauch KW, et al. (2006). Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer 106: 1026-1035.
5. Cantero D, Friess H, Deflorin J, Zimmermann A, Bründler MA, Riesle E, et al. (1997). Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 75:388-395.
6. Cassaro M, Rugge M, Tieppo C, Giacomello L, Velo D, Nitti D, Farinati F (2007). Indefinite for non-invasive neoplasia in gastric intestinal metaplasia: the immunophenotype. J Clin Pathol 60:15-621.
7. Cavallo-Medved D, Mai J, Dosescu J, Sameni M, Sloane BF (2005). Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J Cell Sci 118:1493-1503.
8. Chan CF, Yau TO, Jin DY, Wong CM, Fan ST, Ng IO (2004). Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma. Clin Cancer Res 10:4140-4149.
9. Cozzi PJ, Wang J, Delprado W, Madigan MC, Fairy S, Russel PJ, et al. (2006). Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Hum Pathol 37:1442-1451.
10. Dano K, Behrendt N, Hoyer-Hansen G, Johnson M, Lund LR, Ploug M, et al. (2005). Plasminogen activations and cancer. Thromb Haemost 93:676-681.
11. De Bruin PAF, Griffioen G, Verspaget HW, Verheijen JH, Lamers CBHW (1987). Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps and adenocarcinomas. Cancer Res 47:4654-4657.
12. Dorn J, Harbeck N, Kates R, Magdolen V, Grass L, Soosaipillai A, et al. (2006). Disease processes may be reflected by correlations among tissue kallikrein proteases but not proteolytic factors UPA and PAI-1 in primary ovarian carcinoma. Biol Chem 387:1121-1128.
13. Duffy MJ, Duggan C (2004). The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 37:541-548.
14. Dukes CE (1932). The classification of cancer of the rectum. J Pathol 35:323-332.
15. Ebert MP, Krüger S, Fogeron ML, Chen J, Pross M, Schulz HU, et al. (2005). Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics 5:1693-1704.
16. Farinati F, Herszenyi L, Plebani M, Carraro P, Cardin R, De Paoli M, et al. (1996). Increased levels of cathepsin B and L, urokinase-type plasminogen activator and inhibitor type-1 as an early event in gastric carcinogenesis. Carcino-genesis 17:2581-2587.
17. Ganesh S, Sier CFM, Heerding MH, van Krieken JHJM, Griffioen G, Welwaart K, et al. (1996). Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer 77:1035-1043.
18. Ganesh S, Sier CF, Heerding MM, van Krieken JH, Griffioen G, Welvaart K, et al. (1997). Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes's stage B and C colorectal cancer. Br J Cancer 75:1793-1801.
19. Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G (2005). Lifestyle-related risk factors and chemoprevention for colorectal neoplasia: experience from the large-scale NORCCAP screening trial. Eur J Cancer Prev 14:373-379.
20. Grimaudo V, Hauert J, Kruithof EKO (1988). Diurnal variation of the fibrinolytic system. Thromb Haemost 59:495-499.
21. Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Janicke F, et al. (2001). Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 7:2757-2764.
22. Harbeck N, Schmitt M, Paepke S, Allgayer H, Kates RE (2007). Tumor-associated proteolytic factors UPA and PAI-1: critical appraisal of their relevance in breast cancer and their integration into decision-support algorithm. Crit Rev Clin Lab Sci 44:179-201.
23. Harvey SR, Hurd TC, Markus G, Martinick MI, Penetrante RM, Tan D, et al. (2003). Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin Cancer Res 15:4935-4943.
24. He Y, Liu XD, Chen ZY, Xiong Y, Li K, Dong JH, et al. (2007). Interaction between cancer cells and stromal fibroblasts is required for activation of the UPAR-uPA-MMP2 cascade in pancreatic cancer metastasis. Clin Cancer Res 13:3115-3124.
25. Herszenyi L, Plebani M, Carraro P, De Paoli M, Di Mario F, Kusstatscher S, et al. (1997). Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer. Am J Gastroenterol 92:843-847.
26. Herszenyi L, Plebani M, Carraro P, De Paoli M, Roveroni R, Cardin R, et al. (1999). The role of cysteine and serine proteases in colorectal cancer. Cancer 86:1135-1142.
27. Herszenyi L, Hritz I, Pregun I, Sipos F, Juhasz M, Molnar B, et al. (2007). Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis. World J Gastroenterol 13:676-682.
28. Hirano T, Manabe T, Takeuchi S (1993). Serum cathepsin B levels and urinary excretion of cathepsin B in cancer patients with remote metastasis. Cancer Lett 70:31-44.
29. Huber K, Kirchheimer C, Sedlmayer A, Bell C, Ermler D, Binder BR (1993). Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen. Cancer Res 53:1788-1793.
30. Itoh T, Hayashi Y, Kanamaru T, Morita Y, Suzuki S, Wang W, et al. (2000). Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma. J Gastroenterol Hepatol 15:422-430.
31. Iwamoto J, Mizokami Y, Takahashi K, Nakajima K, Ohtsubo T, Miura S, et al. (2005). Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer and effects of Helico-bacter pylori. Scand J Gastroenterol 40:783-793.
32. Jonkers D, Ernst J, Pladdet J, Stockbrügger R, Hameeteman W (2006). Endoscopic follow-up of 383 patients with colorectal adenoma: an observational study in daily practice. Eur J Cancer Prev 15:202-210.
33. Juarranz M, Calle-Puron ME, Gonzales-Navarro A, Regidor-Poyatos E, Soriano T, Martinez-Hernandez D, et al. (2002). Physical exercise, use of Plantago ovata and aspirin, and reduced risk of colon cancer. Eur J Cancer Prev 11: 465-472.
34. Kim TD, Song KS, Li G, Choi H, Park HD, Lim K, et al. (2006). Activity and expression of urokinase-type plasminogen activator and matrix metallo-proteinases in human colorectal cancer. BMC Cancer 6:211 doi:10.1 1186/ 1471-2407-6-211.
35. Kos J, Nielsen HJ, Krasovec M, Christensen IJ, Cimerman N, Stephens RW, et al. (1998). Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. Clin Cancer Res 4: 1511-1516.
36. Krueger S, Kalinski T, Wolf H, Kellner U, Roessner A (2005). Interactions between human colon carcinoma cells, fibroblasts and monocytic cells in coculture-regulation of cathepsin B expression and invasiveness. Cancer Lett 223:313-322.
37. Lepage C, Remontet L, Launoy G, Trétarre B, Grosclaude P, Colonna M, et al. (2008). Trends in incidence of digestive cancers in France. Eur J Cancer Prev 17:13-17.
38. Leto G, Tumminello FM, Pizzolanti G, Montalto G, Soresi M, Carroccio A, et al. (1997a). Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis. Pancreas 14:22-27.
39. Leto G, Tumminello FM, Pizzolanti G, Montalto G, Soresi M, Gebbia N (1997b). Lysosomal cathepsin B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications. Oncology 54:79-83.
40. Levi F, Lucchini F, La Vecchia C (2006). Trends in cancer mortality in Switzerland, 1980-2001. Eur J Cancer Prev 15:1-9.
41. Liotta LA, Stetler-Stevenson WG (1991). Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51:S5054-5059.
42. Malila N, Virtanen MJ, Virtamo J, Albanes D, Pukkala E (2006). Cancer incidence in a cohort of Finnish male smokers. Eur J Cancer Prev 15:103-107.
43. Matarese VG, Feo CV, Pezzoli A, Trevisani L, Brancaleoni M, Gullini S (2007). Colonoscopy surveillance in asymptomatic subjects with increased risk for colorectal cancer: clinical evaluation and cost analysis of an Italian experience. Eur J Cancer Prev 16:292-297.
44. Murphy G, Atkinson S, Ward R, Garziloric J, Reynolds JJ (1992). The role of plasminogen activators in the regulation of connective tissue metalloprotei-nases. Ann NY Acad Sci 667:1-12.
45. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, et al. (1994). Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54: 2900-2907.
46. Niedergethmann M, Hildenbrand R, Wolf G, Verbeke CS, Richter A, Post S (2000). Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection. Int J Pancreatol 28: 31-39.
47. Niedergethmann M, Wostbrock B, Sturm JW, Willeke F, Post S, Hildenbrand R (2004). Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma. Pancreas 29:204-211.
48. Obermeyer K, Krueger S, Peters B, Falkenberg B, Roessner A, Röcken C (2007). The expression of low density lipoprotein receptor-related protein in colorectal carcinoma. Oncol Rep 17:361-367.
49. Offersen BV, Pfeiffer P, Andreasen P, Overgaard J (2007). Urokinase plasmino-gen activator and plasminogen activator inhibitor type-1 in normal-cell lung cancer: relation to prognosis and angiogenesis. Lung Cancer 43:43-50.
50. Padilla D, Cubo T, Molina JM, Garcia M, De la Osa G, Palomino T, et al. (2003). Prognostic significance and clinical utility of serum and immunohistochemical cathepsin B levels in colorectal cancer. An Med Interna 20:521-525.
51. Plebani M, Herszenyi L, Cardin R, Roveroni G, Carraro P, De Paoli M, et al. (1995). Cysteine and serine proteases in gastric cancer. Cancer 76: 367-375.
52. Plebani M, Herszenyi L, Carraro P, De Paoli M, Roveroni G, Cardin R, et al. (1997). Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. Clin Exp Metastasis 15:418-425.
53. Rozen P (2004). Cancer of the gastrointestinal tract: early detection or early prevention? Eur J Cancer Prev 13:71-75.
54. Sanjoaquin MS, Choodari-Oskooei B, Dolbear C, Putcha V, Sehgal A, Key T, et al. (2007). Colorectal cancer incidence, mortality and survival in South-east England between 1972 and 2001. Eur J Cancer Prev 16:10-16.
55. Sebzda T, Saleh Y, Gburek J, Warwas M, Andrzejak R, Siewinski M, et al. (2006). Total and lipid-bound plasma sialic acid and diagnostic markers in colorectal cancer patients: correlation with cathepsin B expression in progression to Dukes stage. J Exp Ther Oncol 5:223-229.
56. Shuja S, Sheahan K, Murnane MJ (1991). Cysteine endopeptidase activity levels in normal human tissues, colorectal adenomas and carcinomas. Int J Cancer 49:341-346.
57. Sier CFM, Verspaget HW, Griffioen G, Ganesh S, Vloedgraven JH, Lamers CB (1993). Plasminogen activators in normal tissue and carcinomas of the human esophagus and stomach. Gut 34:80-85.
58. Sier CF, Vloedgraven HJM, Ganesh S, Griffioen G, Quax PH, Verheijen JH, et al. (1994). Inactive urokinase and increased levels of its inhibitors type 1 in colorectal cancer liver metastasis. Gastroenterology 107:1449-1456.
59. Sinha AA, Morgan JL, Buus RJ, Ewing SL, Fernandes ET, Lee C, et al. (2007). Cathepsin B expression is similar in African-American and Caucasian prostate cancer patients. Anticancer Res 27:3135-3141.
60. Skrzydlewska E, Sulkowska M, Koda M, Sulkowski S (2005). Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol 11:1251-1266.
61. Sloane BF (1990). Cathepsin B and cystatins: evidence for a role in cancer progression. Semin Cancer 1:137-152.
62. Song KS, Lee A, Choi JR, Kwon OH (1995). Diagnostic efficacy of plasma urokinase-type plasminogen activator and plasminogen activator inhibitor-2 in differentiation of hepatocellular carcinoma from cirrhosis. Thromb Haemost 74:864-867.
63. Speleman L, Kerrebijn JD, Look MP, Meeuwis CA, Fockens JA, Berns EM (2007). Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma. Head Neck 29:341-350.
64. Talieri M, Papadopoulou S, Scorilas A, Xynopoulos D, Arnogianaki N, Plataniotis G, et al. (2004). Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma. Cancer Lett 205:97-106.
65. Troy AM, Sheahan K, Mulcahy HE, Duffy MJ, Hyland JM, O'Donoughe DP (2004). Expression of cathepsin B and L antigen and activity is associated with early colorectal progression. Eur J Cancer 40:1610-1616.
66. Turnbull RB, Kyle K, Watson FR, Spratt J (1967). Cancer of the colon: the influence of the no-touch isolation on the survival rates. Ann Surg 166: 420-427.
67. Werle B, Kotzsch M, Lah TT, Kos J, Gabrijelcic-Geiger D, Spiess E, et al. (2004). Cathepsin B, plasminogen activator-inhibitor (PAI-1) and plasminogen activator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res 24:4147-4161.
68. Yang JL, Seetoo DQ, Wang Y, Ranson M, Berney CR, Ham JM, et al. (2000). Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. Int J Cancer 89:431-439.
69. Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB (2000). Invasion and metastasis of heptocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol 126:641-646.
70. Zhou L, Hayashi Y, Itoh T, Wang W, Rui J, Itoh H (2000). Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma. Pathol Int 50:392-397.